![Søren Mouritsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Rodrigo Vazquez-Lombardi | M | - |
Engimmune Therapeutics AG
![]() Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | 3 years |
Bent K. Jakobsen | M | - |
Engimmune Therapeutics AG
![]() Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | 2 years |
Lars Nieba | M | 56 |
Engimmune Therapeutics AG
![]() Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Nikolai Søren Kirkby | M | - |
University of Copenhagen
| 4 years |
Jesper Nerlov | M | 56 |
University of Copenhagen
| 8 years |
Anders Hove | M | 58 |
University of Copenhagen
| 6 years |
Christian Meyersahm | M | - |
University of Copenhagen
| 4 years |
Soren Mogelsvang | M | 52 |
University of Copenhagen
| 4 years |
Liselotte Hyveled | F | 58 |
University of Copenhagen
| 1 years |
Jacob Rosenberg | M | 59 |
University of Copenhagen
| 3 years |
Hanne Andersen | F | - |
University of Copenhagen
| 4 years |
Jette Nygaard-Andersen | F | 55 |
University of Copenhagen
| 2 years |
Christian Lundgren | M | 58 |
University of Copenhagen
| 3 years |
Flemming Wagner | M | - |
University of Copenhagen
| 7 years |
Nicolas Nemery | M | - |
University of Copenhagen
| 4 years |
Jacob Vinther | M | 58 |
University of Copenhagen
| 4 years |
Guggi Heine Remme Kofod | M | - |
University of Copenhagen
| 6 years |
Jesper Alling Coverdale Kofoed | M | - |
University of Copenhagen
| 3 years |
Tomasz Piec | M | - |
University of Copenhagen
| 4 years |
Lars Jørn Hvidtfeldt Nielsen | M | 57 |
University of Copenhagen
| 1 years |
Birgitte Nauntofte | M | 66 |
University of Copenhagen
| 3 years |
Inger Ørum Kirk | F | 59 |
University of Copenhagen
| 3 years |
Elise Hauge | F | 57 |
University of Copenhagen
| 1 years |
Lars Løkke Rasmussen | M | 60 |
University of Copenhagen
| 3 years |
Nils Thomas Weincke | M | 61 |
University of Copenhagen
| 4 years |
Malene Lei Raben | F | - |
University of Copenhagen
| 3 years |
Adam Erritzøe | M | - |
University of Copenhagen
| 5 years |
Mads Hørberg | M | - |
University of Copenhagen
| 1 years |
Amanda Tonsgaard | F | - |
University of Copenhagen
| 5 years |
Jesper Gromada | M | - |
University of Copenhagen
| 3 years |
Peter Wulff | M | - |
University of Copenhagen
| 1 years |
Christian Grane | M | - |
University of Copenhagen
| 4 years |
Sai Reddy | M | - |
Engimmune Therapeutics AG
![]() Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | - |
Jens Munch Holst | M | 60 |
University of Copenhagen
| 1 years |
Troels Albrechtsen | M | - |
University of Copenhagen
| 1 years |
Kresten Buch | M | - |
University of Copenhagen
| 5 years |
Lars Friis Mikkelsen | M | 56 |
University of Copenhagen
| 3 years |
Anja E. H. Holm | M | 59 |
University of Copenhagen
| 3 years |
Lars Lunde | M | 51 |
University of Copenhagen
| 6 years |
Morten Weicher Weicher | M | - |
University of Copenhagen
| - |
Jakob Poulsen | M | - |
University of Copenhagen
| 6 years |
Torsten Lodberg Smed | M | 54 |
University of Copenhagen
| 5 years |
Arne Gerlyng-Hansen | M | 68 |
University of Copenhagen
| 7 years |
Amar A. Sethi | M | - |
University of Copenhagen
| 3 years |
Jakob Riis | M | 58 |
University of Copenhagen
| 1 years |
Karen Elisabeth Heltoft | F | - |
University of Copenhagen
| 4 years |
Niels Kærgård | M | 81 |
University of Copenhagen
| 3 years |
Niels Tækker Foged | M | 63 |
University of Copenhagen
| 3 years |
Heidi Schütt Larsen | F | - |
University of Copenhagen
| 1 years |
Carl Bek-Nielsen | M | 51 |
University of Copenhagen
| 4 years |
Jörgen Axel Thorball | M | 62 |
University of Copenhagen
| 3 years |
Jesper Theill Eriksen | M | 56 |
University of Copenhagen
| 3 years |
Thea Wulff Olesen | F | 58 |
University of Copenhagen
| 3 years |
Ole Sibbesen | M | - |
University of Copenhagen
| 3 years |
David Leeds | M | 55 |
University of Copenhagen
| 4 years |
Kim Lennart Dueholm | M | 61 |
University of Copenhagen
| 3 years |
Thomas Tscherning | M | - |
University of Copenhagen
| 3 years |
Mads Krogsgaard Thomsen | M | 63 |
University of Copenhagen
| 8 years |
Jens Due Olsen | M | 60 |
University of Copenhagen
| 1 years |
Michael Rasmussen | M | 59 |
University of Copenhagen
| 1 years |
Robert B. Madsen | M | - |
University of Copenhagen
| 4 years |
Birgitte Rønnow | M | - |
University of Copenhagen
| 3 years |
Tune Marschall | M | - |
University of Copenhagen
| 1 years |
Henrik Rasmussen | M | 65 |
University of Copenhagen
| 3 years |
Lykke Friis | M | 54 |
University of Copenhagen
| 6 years |
Anders Stahlschmidt | M | 57 |
University of Copenhagen
| 3 years |
Finn Sture Madsen | M | 57 |
University of Copenhagen
| 4 years |
Jens Fricke | M | 59 |
University of Copenhagen
| 1 years |
Kim Vilbour Andersen | M | - |
University of Copenhagen
| 3 years |
Zhan Li | M | 62 |
University of Copenhagen
| 2 years |
Dirk Schmelzer | M | 57 |
University of Copenhagen
| 4 years |
Hans Henrik Chrois Christensen | M | 59 |
University of Copenhagen
| 3 years |
Henrik N. Rasmussen | M | - |
University of Copenhagen
| 3 years |
Henriette Nielsen | F | 58 |
University of Copenhagen
| 4 years |
Bjørn Slot Jensen | M | - |
University of Copenhagen
| 4 years |
Peter Lindberg | M | - |
University of Copenhagen
| 4 years |
Dorte Westh Lehrmann | F | - |
University of Copenhagen
| 4 years |
Asbjørn Christoffersen | M | - |
University of Copenhagen
| 7 years |
Lone Lindsby | M | - |
University of Copenhagen
| 4 years |
Manuel Lopez-Figueroa | M | - |
University of Copenhagen
| 5 years |
Anne-Mette de Place Filippini | F | - |
University of Copenhagen
| 1 years |
Philip Christiani | M | - |
University of Copenhagen
| 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
Denmark | 78 | 95.12% |
Switzerland | 4 | 4.88% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Søren Mouritsen
- Personal Network